Conflict of Interest (COI) Policy
The CAP, ASCP, and ASCO require that any individual influencing the content of Practice Guidelines provide disclosure of the existence and extent of any financial interest relevant to the content of these guidelines on molecular biomarkers, tests or therapies associated with gastroesophageal adenocarcinoma. The intent of disclosures is to provide transparency regarding any relationship that may bias an individual's participation or work product of which, if known, could give the perception of bias. Disclosures of actual or perceived conflicts of interest (COI) of all members of the practice guidelines development group allow users to interpret recommendations in light of COIs. The COI policy is based on and consistent with the recommendations in the Institute of Medicine's 2011 report, Clinical Practice Guidelines We Can Trust. 1 Prior to acceptance on the expert or advisory panel, potential members completed a joint guideline conflict of interest (COI) disclosure process, whose policy and form (in effect December 2014) require disclosure of material financial interest in, or potential for benefit of significant value from the guideline's development or its recommendations 12 months prior through the time of publication. The potential members completed the COI disclosure form, listing any relationship that could be interpreted as constituting an actual, potential, or apparent conflict. Examples of conflicts of interest with relevant commercial entities were provided to the participants using a Conflict of Interest (COI) Policy List of Affected Companies For the CAP/ASCP/ASCO HER2 Testing in Gastroesophageal Cancer document.
The CAP/ASCP/ASCO joint guideline COI policy uses the following criteria to define relationships that could be interpreted as constituting an actual, potential, or apparent conflict:
1. Stock options or bond holdings in a relevant commercial entity or self-directed pension plan 2. Research grants from a relevant commercial entity 3. Employment (full or part-time) by a relevant commercial entity 4. Ownership or partnership in relevant corporate entities, including equities and stock options 5. Consulting or advisory fees from relevant commercial entities 6. Other remuneration from relevant commercial entities, including free or discounted products or equipment, trips, accommodations, tickets to sports or entertainment events, etc. 7. Non-remunerative positions of influence in a relevant commercial entity such as officer, board member, trustee, spokesperson, advisor 8. Royalties from relevant commercial entities 9. Intellectual property rights, i.e., patents issued or pending 10. Lecture or speaker fees/honoraria from relevant commercial entities 1. Should HER2 testing be requested for every patient diagnosed with gastroesophageal adenocarcinoma? 2. Which of the tumor specimen(s) is the most appropriate to perform HER2 testing?
• Biopsy specimen from primary tumor All expert panelists participated in the systematic evidence review. The title-abstract review was primarily reviewed by the methodologist with the assistance of the co-chairs. The full text review was performed in duplicate by two members of the expert panel. The data was extracted by the methodologist and audited by members of the expert panel. All expert panelists and the methodologist performed adjudication of the conflicts. Articles meeting the inclusion criteria were assessed for strength of evidence, methodological rigor, and confirmation of validity by the methodologist. Supplemental Figure 1 displays the results of the literature review. All articles were available as discussion or background references. All members of the expert panel participated in developing draft recommendations, the assignment of the strength of recommendations based on the extracted evidence, reviewing open comment feedback, finalizing and approving final recommendations and writing/editing of the manuscript.
Peer Review
A public open comment period was held from December 8, 2015 through January 11, 2016. Twenty draft statements were posted online on the ASCP Web site www.ascp.org. The open comment period was publicized via joint society communications announcements and the following societies were deemed to have interest: The website received 294 comments in total (Agree as written, Agree with suggested modification and Disagree responses were captured). All draft recommendations achieved between 82% to 95% agreement as written. Teams of 2 of expert panel members were assigned the draft statements for 2-3 key questions. The teams reviewed all comments received and provide an overall summary to the rest of the panel. Following panel discussion, and the final quality of evidence assessment, the panel members determined whether to maintain the original draft recommendation as is, revise it with minor language change, or consider it as a major recommendation change. The panel modified 1 draft recommendation and combined 4 draft recommendations based on the feedback from the public comment period and the panel's discussion and considered judgment process. The panel decided that general recommendations about quality assurance, turnaround time, and specimen handling were best suited as part of the discussion, and would be included in the body of the manuscript rather than as formal recommendations. Resolution of all changes was obtained by majority consensus of the panel using nominal group technique (rounds of email discussion and multiple edited recommendations) amongst the panel members. The final recommendations were approved by the expert panel with a formal vote. The panel considered the risks and benefits throughout the whole process in their considered judgment process. Formal cost analysis or cost effectiveness was not performed.
Organizational review was instituted to review and approve the guideline. An independent review panel (IRP) representing the CAP Council on Scientific Affairs was nominated to review and approve the guideline. The CAP IRP was masked to the expert panel and vetted through a COI process. ASCP assigned the review to a Special Review Panel at the discretion of the ASCP Executive Office and the Board of Directors. The ASCO approval process required the review and approval by the Clinical Practice Guidelines Committee.
Dissemination Plans
Final dissemination of the guideline will be a joint process between the three organizations. There are plans to host a resource page which will include a link to the manuscript and supplement, summary of the recommendations, social media as well as patient information guides. The guideline will be promoted and presented at various society meetings.
Systematic Evidence Review (SER)
The objective of the SER was to develop an evidence-based guideline to determine what the optimal testing algorithm is for the assessment of HER2 status, and to determine strategies that can help ensure optimal performance, interpretation and reporting of established assays in patients with gastroesophageal adenocarcinoma. The guideline was developed to help establish standards for HER2 testing in gastroesopageal adenocarcinima to help guide targeted therapies, and advance personalized care for patients. The scope of the SER and the KQs were established by the EP in consultation with the methodologist prior to beginning the literature search. The literature search of the electronic databases was conducted in two arms -one combined medical subject headings (MeSH) and keywords to address the concepts of esophagogastric neoplasms, Her-2/ErbBB-2, and therapy (e.g., monoclonal antibodies/antineoplastic agents/molecular targeted therapy), and the second combined MeSH terms and keywords for esophagogastric neoplasms, Her-2/ErbBB-2 and laboratory testing methods. The results of both arms of the search were combined and deduplicated.
Search and Selection
In addition to the searches of electronic databases, a search for grey (unindexed) literature was completed that included a review of guideline repository sites (e.g., Agency for Healthcare Research and Quality, Guidelines International Network), the Cochrane Library, Prospero, and relevant organizations' websites.
The Ovid, PubMed, and Scopus search strategies are included as Supplemental Figure 2 .
Selection at all levels was based on predetermined inclusion/exclusion criteria. 
Outcomes of Interest
The primary outcomes of interest included survival outcomes and performance characteristics of laboratory testing assays. Survival outcomes included: overall survival (OS), disease-free survival (DFS), progression free survival (PFS), response rate, recurrence-free survival, time to recurrence, response to therapy (e.g., complete and partial response). Laboratory data and test performing characteristics included sensitivity and specificity of testing methods, and concordance.
Data Extraction & Management
Following the initial search, titles and abstracts of retrieved studies were reviewed by the methodologist and co-chairs for relevancy. Conflicts were resolved by initial reviewers and further adjudicated by a project co-chair, if necessary. Titles and abstracts advanced to full text review if the screener felt the study was relevant to the guideline, the laboratory was laboratory-focused or clinically-focused based on the population of interest and the intervention or test of interest, and the article met the established study design specifications:
For Clinical studies:
Included were: 1. Systematic reviews with or without meta-analyses 2. Other reviews (consensus, expert panel, guidelines) 3. Randomized trials (Phase II or III, placebo-controlled, blinded) Full text articles were reviewed for relevancy by two expert panel members to determine eligibility, and conflicts were resolved by the initial reviewers and further adjudicated by a project co-chair, if necessary. In cases of duplication of reporting study results, the most inclusive were retained. Articles advanced to data extraction if they addressed at least one of the key questions, contained measurable data, and were within the project's scope and met the previously described inclusion/exclusion criteria. Data extraction was performed by a methodologist and audited by one expert panel member. Any discrepancies in data extraction were resolved by discussion. A bibliographic database was established in DistillerSR (Ontario, Canada) and EndNote (Thomson Reuters, Carlsbad, CA) to track all literature identified and reviewed during the study.
Quality Assessment Methods
An assessment of the quality of the evidence was performed for all retained studies following application of the inclusion and exclusion criteria. Using this method, studies deemed be of low quality would not be excluded from the systematic review, but would be retained and their methodological strengths and weaknesses discussed where relevant. Studies would be assessed by confirming the presence of items related to both internal and external validity, and which are all associated with methodological rigor and a decrease in the risk of bias. These items were assessed as being either yes, no, partial, not reported (NR), or not applicable (N/A) in the following way: Systematic Reviews (SRs) and Meta-analyses were assessed for quality by confirming the following attributes were considered and incorporated in its design as recommended by the Institute of Medicine (IOM). 1 (Summarized in Supplemental Table 1) • Included a multidisciplinary panel • Patient preferences were considered • Important patient sub-types were considered • Methods were well-described and reproducible • Information on potential conflicts of interest were gathered and disclosed • Quality of the evidence was assessed • Strength of the evidence was rated • Sources of funding are disclosed Meta-analyses (M-As) were assessed in a similar fashion to SRs:
• Based on a systematic review • Methods were well-described and reproducible • Quality of the evidence was assessed • Any planned pooling was stated a priori • Limitations of the analysis are discussed • Sources of funding are disclosed Randomized Control Trials (RCTs) and Quasi-RCTs were assessed for quality according to reporting and full description of:
• Randomization method fully-described • Treatment allocation was concealed • Sample size was sufficient • Validated and reliable measures • Details on any blinding was provided
• Provided details of all planned analyses • Stated the expected effect size and described the statistical power calculation • Reported the length of follow-up • Provided a description of the baseline characteristics for all patients by treatment/assessment arm • Sources of funding are disclosed Non-randomized clinical trials (NRCTs), prospective cohort studies (PCS), and retrospective cohort studies (RCS) were assessed according to:
• Balance between treatment/assessment groups • Reporting of baseline characteristics • Reporting if any adjustments were made where baseline differences were detected • Sources of funding Supplemental Table 1 -6 summarizes the quality assessment results by study design and overall risk of bias assessment.
Strength of Recommendations
The expert panel reviewed all the synthesized evidence and drafted recommendations during one of the in-person meetings. For each recommendation, there was a discussion on the quality of the evidence available, the harms versus benefits, values, as well as limitations. The strength of recommendations designations and rationale are listed in Supplemental Table 7 . 
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